iShares MSCI Kokusai ETF (NYSEARCA:TOK) Stock Short Interest Declines 47.8%
by Sarita Garza · The Markets DailyiShares MSCI Kokusai ETF (NYSEARCA:TOK – Get Free Report) was the recipient of a significant decline in short interest in September. As of September 30th, there was short interest totaling 2,286 shares, a decline of 47.8% from the September 15th total of 4,376 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 2,459 shares, the short-interest ratio is currently 0.9 days.
Institutional Investors Weigh In On iShares MSCI Kokusai ETF
An institutional investor recently raised its stake in iShares MSCI Kokusai ETF stock. Citadel Advisors LLC increased its position in iShares MSCI Kokusai ETF (NYSEARCA:TOK – Free Report) by 16.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,388 shares of the company’s stock after acquiring an additional 922 shares during the period. Citadel Advisors LLC owned approximately 0.39% of iShares MSCI Kokusai ETF worth $957,000 as of its most recent SEC filing.
iShares MSCI Kokusai ETF Stock Performance
TOK stock traded down $0.96 during trading on Wednesday, reaching $153.91. 3,264 shares of the company were exchanged, compared to its average volume of 2,526. The stock’s 50 day moving average price is $154.41 and its 200 day moving average price is $149.60. iShares MSCI Kokusai ETF has a 52-week low of $129.49 and a 52-week high of $156.77. The company has a market cap of $238.56 million, a P/E ratio of 22.74 and a beta of 0.96.
iShares MSCI Kokusai ETF Company Profile
The iShares MSCI Kokusai ETF (TOK) is an exchange-traded fund that is based on the MSCI Kokusai (World ex Japan) index. The fund tracks a market cap-weighted index of large- and mid-cap developed market stocks outside of Japan. TOK was launched on Dec 10, 2007 and is managed by BlackRock.
See Also
- Five stocks we like better than iShares MSCI Kokusai ETF
- High Voltage Returns: Navitas Rewires AI Data Centers
- Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built
- Albertsons Is Betting on a Turnaround—But Will It Pay Off?
- Venezuela’s Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit